135 related articles for article (PubMed ID: 23893067)
1. Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics.
Woodward DF; Wang JW; Poloso NJ
Pharmacol Rev; 2013; 65(4):1135-47. PubMed ID: 23893067
[TBL] [Abstract][Full Text] [Related]
2. Prostamides (prostaglandin-ethanolamides) and their pharmacology.
Woodward DF; Liang Y; Krauss AH
Br J Pharmacol; 2008 Feb; 153(3):410-9. PubMed ID: 17721551
[TBL] [Abstract][Full Text] [Related]
3. A historical perspective and recent advances in prostamide research and therapeutics.
Burk RM; Woodward DF
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):413-21. PubMed ID: 17659482
[TBL] [Abstract][Full Text] [Related]
4. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias.
Khidhir KG; Woodward DF; Farjo NP; Farjo BK; Tang ES; Wang JW; Picksley SM; Randall VA
FASEB J; 2013 Feb; 27(2):557-67. PubMed ID: 23104985
[TBL] [Abstract][Full Text] [Related]
5. Bimatoprost: a novel antiglaucoma agent.
Woodward DF; Phelps RL; Krauss AH; Weber A; Short B; Chen J; Liang Y; Wheeler LA
Cardiovasc Drug Rev; 2004; 22(2):103-20. PubMed ID: 15179448
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression.
Liang Y; Li C; Guzman VM; Evinger AJ; Protzman CE; Krauss AH; Woodward DF
J Biol Chem; 2003 Jul; 278(29):27267-77. PubMed ID: 12724323
[TBL] [Abstract][Full Text] [Related]
7. Anandamide-derived prostamide F2α negatively regulates adipogenesis.
Silvestri C; Martella A; Poloso NJ; Piscitelli F; Capasso R; Izzo A; Woodward DF; Di Marzo V
J Biol Chem; 2013 Aug; 288(32):23307-21. PubMed ID: 23801328
[TBL] [Abstract][Full Text] [Related]
8. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.
Woodward DF; Krauss AH; Wang JW; Protzman CE; Nieves AL; Liang Y; Donde Y; Burk RM; Landsverk K; Struble C
Br J Pharmacol; 2007 Feb; 150(3):342-52. PubMed ID: 17179945
[TBL] [Abstract][Full Text] [Related]
9. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes.
Liang Y; Woodward DF; Guzman VM; Li C; Scott DF; Wang JW; Wheeler LA; Garst ME; Landsverk K; Sachs G; Krauss AH; Cornell C; Martos J; Pettit S; Fliri H
Br J Pharmacol; 2008 Jul; 154(5):1079-93. PubMed ID: 18587449
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS.
Koda N; Tsutsui Y; Niwa H; Ito S; Woodward DF; Watanabe K
Arch Biochem Biophys; 2004 Apr; 424(2):128-36. PubMed ID: 15047184
[TBL] [Abstract][Full Text] [Related]
11. Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors.
Chen J; Lu RT; Lai R; Dinh T; Paul D; Venadas S; Wheeler LA
Curr Eye Res; 2009 Mar; 34(3):184-95. PubMed ID: 19274525
[TBL] [Abstract][Full Text] [Related]
12. Bimatoprost, prostamide activity, and conventional drainage.
Wan Z; Woodward DF; Cornell CL; Fliri HG; Martos JL; Pettit SN; Wang JW; Kharlamb AB; Wheeler LA; Garst ME; Landsverk KJ; Struble CS; Stamer WD
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4107-15. PubMed ID: 17724194
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic formation of prostamide F2alpha from anandamide involves a newly identified intermediate metabolite, prostamide H2.
Yang W; Ni J; Woodward DF; Tang-Liu DD; Ling KH
J Lipid Res; 2005 Dec; 46(12):2745-51. PubMed ID: 16150817
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of bimatoprost.
Cantor LB
Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):151-7. PubMed ID: 16922657
[TBL] [Abstract][Full Text] [Related]
15. Cellular basis for bimatoprost effects on human conventional outflow.
Stamer WD; Piwnica D; Jolas T; Carling RW; Cornell CL; Fliri H; Martos J; Pettit SN; Wang JW; Woodward DF
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5176-81. PubMed ID: 20435598
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin ethanolamides attenuate damage in a human explant colitis model.
Nicotra LL; Vu M; Harvey BS; Smid SD
Prostaglandins Other Lipid Mediat; 2013 Jan; 100-101():22-9. PubMed ID: 23380599
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).
Woodward DF; Krauss AH; Chen J; Liang Y; Li C; Protzman CE; Bogardus A; Chen R; Kedzie KM; Krauss HA; Gil DW; Kharlamb A; Wheeler LA; Babusis D; Welty D; Tang-Liu DD; Cherukury M; Andrews SW; Burk RM; Garst ME
J Pharmacol Exp Ther; 2003 May; 305(2):772-85. PubMed ID: 12606640
[TBL] [Abstract][Full Text] [Related]
18. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products.
Woodward DF; Carling RW; Cornell CL; Fliri HG; Martos JL; Pettit SN; Liang Y; Wang JW
Pharmacol Ther; 2008 Oct; 120(1):71-80. PubMed ID: 18700152
[TBL] [Abstract][Full Text] [Related]
20. A case hypersensitive to bimatoprost and dexamethasone.
Li X; Liu G; Wang Y; Yu W; Xiang H; Liu X
J Ocul Pharmacol Ther; 2011 Oct; 27(5):519-23. PubMed ID: 21936632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
